Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy

Frontiers in Cardiovascular Medicine(2022)10.3389/fcvm.2022.907597Source: DataRank Database

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy is a research paper published in Frontiers in Cardiovascular Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.55)OA: goldTopics (26)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Carlos Bermúdez,Cyril Ayuk Mbeng Takem Baiyee,Brandon Rodgers ORCID,Samir M. Parikh ORCID,Salem Almaani ORCID

Live enrichment

PubMed:35898273 PMC:PMC9309481 OpenAlex:https://openalex.org/W4285005026

National Institutes of Health

Grant: 3UL1TR001450-06S1

South Carolina Clinical & Translational Research Institute (SCTR)

National Institutes of Health

Grant: 5TL1TR002735-04

NRSA Training Core

FWCI

0.55

Citation Percentile

0.6%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.907597/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.907597/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.907597/full

journalhttps://doi.org/10.3389/fcvm.2022.907597

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35898273

Fields of Study

Amyloidosis: Diagnosis, Treatment, OutcomesTakotsubo Cardiomyopathy and Associated PhenomenaCardiac electrophysiology and arrhythmias03 medical and health sciences0302 clinical medicine

Keywords

MedicineRestrictive cardiomyopathyHeart failureInternal medicineCardiomyopathyCardiologyDiscontinuationEjection fractionCoronary artery diseaseCardiac amyloidosisHypertrophic cardiomyopathyAsymptomaticAmyloidosisPharmacologylight chaintransthyretinRC666-701Medicine and Health Sciences610Diseases of the circulatory (Cardiovascular) systemCardiovascular Medicine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being